Rajeev Indrajit Desai, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Nicotine | 9 | 2024 | 686 | 2.420 |
Why?
|
| Space Flight | 3 | 2023 | 193 | 2.110 |
Why?
|
| Behavior, Animal | 8 | 2018 | 1872 | 1.790 |
Why?
|
| Nicotinic Agonists | 6 | 2020 | 272 | 1.760 |
Why?
|
| Saimiri | 7 | 2024 | 335 | 1.550 |
Why?
|
| Weightlessness | 2 | 2022 | 91 | 1.520 |
Why?
|
| Cocaine | 14 | 2017 | 996 | 1.500 |
Why?
|
| Alkaloids | 3 | 2024 | 190 | 1.490 |
Why?
|
| Cannabinoids | 2 | 2023 | 170 | 1.480 |
Why?
|
| Dopamine Uptake Inhibitors | 9 | 2017 | 307 | 1.080 |
Why?
|
| Self Administration | 3 | 2024 | 380 | 1.040 |
Why?
|
| Benztropine | 4 | 2017 | 17 | 1.040 |
Why?
|
| Dopamine Agonists | 5 | 2010 | 355 | 0.960 |
Why?
|
| Receptors, Dopamine D1 | 4 | 2007 | 286 | 0.960 |
Why?
|
| Cosmic Radiation | 1 | 2023 | 13 | 0.950 |
Why?
|
| Receptors, Nicotinic | 2 | 2018 | 498 | 0.860 |
Why?
|
| Methamphetamine | 3 | 2014 | 157 | 0.810 |
Why?
|
| Nicotinic Antagonists | 3 | 2018 | 96 | 0.770 |
Why?
|
| Dose-Response Relationship, Drug | 19 | 2024 | 10914 | 0.760 |
Why?
|
| Behavior, Addictive | 2 | 2016 | 457 | 0.730 |
Why?
|
| Central Nervous System Stimulants | 5 | 2014 | 1162 | 0.630 |
Why?
|
| Receptor, Cannabinoid, CB1 | 2 | 2023 | 145 | 0.610 |
Why?
|
| 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine | 3 | 2006 | 54 | 0.580 |
Why?
|
| Vaccines | 2 | 2016 | 842 | 0.560 |
Why?
|
| Fentanyl | 3 | 2023 | 413 | 0.550 |
Why?
|
| Motor Activity | 7 | 2013 | 2715 | 0.550 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 4 | 2013 | 421 | 0.520 |
Why?
|
| Conditioning, Operant | 5 | 2024 | 311 | 0.520 |
Why?
|
| Dopamine Agents | 2 | 2014 | 186 | 0.510 |
Why?
|
| Respiratory Insufficiency | 1 | 2023 | 1211 | 0.500 |
Why?
|
| Benzazepines | 5 | 2010 | 320 | 0.500 |
Why?
|
| Smoke | 1 | 2016 | 229 | 0.480 |
Why?
|
| Tobacco Use Disorder | 2 | 2020 | 692 | 0.470 |
Why?
|
| Substance Withdrawal Syndrome | 2 | 2020 | 625 | 0.440 |
Why?
|
| Astronauts | 2 | 2023 | 80 | 0.400 |
Why?
|
| Rats | 14 | 2023 | 24248 | 0.400 |
Why?
|
| Dopamine | 5 | 2018 | 1584 | 0.390 |
Why?
|
| Immunization | 1 | 2015 | 1254 | 0.370 |
Why?
|
| Cholinergic Agents | 1 | 2010 | 96 | 0.360 |
Why?
|
| Biogenic Monoamines | 1 | 2010 | 50 | 0.360 |
Why?
|
| Blinking | 2 | 2007 | 137 | 0.360 |
Why?
|
| Nanotechnology | 1 | 2016 | 706 | 0.360 |
Why?
|
| Animals | 31 | 2024 | 169600 | 0.350 |
Why?
|
| Discrimination Learning | 6 | 2015 | 281 | 0.310 |
Why?
|
| Drug Interactions | 4 | 2018 | 1447 | 0.290 |
Why?
|
| Immunologic Factors | 1 | 2015 | 1572 | 0.260 |
Why?
|
| Drug Delivery Systems | 1 | 2016 | 2229 | 0.240 |
Why?
|
| Atropine Derivatives | 1 | 2023 | 5 | 0.240 |
Why?
|
| Generalization, Stimulus | 2 | 2003 | 13 | 0.240 |
Why?
|
| Drug Inverse Agonism | 1 | 2023 | 12 | 0.240 |
Why?
|
| Nucleus Accumbens | 3 | 2018 | 358 | 0.230 |
Why?
|
| Smoking Cessation | 1 | 2016 | 2083 | 0.230 |
Why?
|
| Rats, Sprague-Dawley | 9 | 2017 | 8285 | 0.220 |
Why?
|
| Cholinergic Agonists | 1 | 2003 | 74 | 0.220 |
Why?
|
| Heroin | 1 | 2022 | 116 | 0.200 |
Why?
|
| Oxycodone | 1 | 2022 | 147 | 0.190 |
Why?
|
| Male | 26 | 2024 | 354311 | 0.180 |
Why?
|
| Piperazines | 3 | 2017 | 2502 | 0.180 |
Why?
|
| Naltrexone | 1 | 2022 | 306 | 0.180 |
Why?
|
| Ligands | 3 | 2013 | 3300 | 0.170 |
Why?
|
| Eating | 2 | 2017 | 1563 | 0.170 |
Why?
|
| Reinforcement Schedule | 3 | 2017 | 127 | 0.170 |
Why?
|
| Membrane Transport Proteins | 1 | 2005 | 1041 | 0.170 |
Why?
|
| Primates | 1 | 2021 | 547 | 0.160 |
Why?
|
| Self Stimulation | 1 | 2017 | 47 | 0.150 |
Why?
|
| Narcotic Antagonists | 1 | 2022 | 561 | 0.150 |
Why?
|
| Mecamylamine | 2 | 2010 | 29 | 0.150 |
Why?
|
| Excitatory Amino Acid Transporter 2 | 1 | 2018 | 80 | 0.150 |
Why?
|
| Racemases and Epimerases | 1 | 2017 | 113 | 0.140 |
Why?
|
| Drug Tolerance | 2 | 2012 | 377 | 0.140 |
Why?
|
| Analgesics, Opioid | 2 | 2023 | 3722 | 0.140 |
Why?
|
| Amphetamine | 1 | 2018 | 229 | 0.140 |
Why?
|
| Anabasine | 1 | 2016 | 6 | 0.140 |
Why?
|
| Mice | 9 | 2023 | 81766 | 0.140 |
Why?
|
| Locomotion | 1 | 2018 | 376 | 0.130 |
Why?
|
| Sleep Deprivation | 1 | 2022 | 815 | 0.130 |
Why?
|
| Cognition | 2 | 2023 | 6844 | 0.130 |
Why?
|
| Cotinine | 1 | 2016 | 210 | 0.130 |
Why?
|
| Microdialysis | 2 | 2017 | 160 | 0.130 |
Why?
|
| Berberine | 1 | 2015 | 25 | 0.130 |
Why?
|
| Fear | 2 | 2020 | 1452 | 0.120 |
Why?
|
| Models, Animal | 1 | 2021 | 2175 | 0.120 |
Why?
|
| Drug Partial Agonism | 1 | 2014 | 24 | 0.120 |
Why?
|
| Pyridines | 2 | 2016 | 2841 | 0.120 |
Why?
|
| Piperidines | 1 | 2022 | 1630 | 0.120 |
Why?
|
| Membrane Glycoproteins | 1 | 2005 | 3761 | 0.120 |
Why?
|
| Protein Isoforms | 1 | 2018 | 1731 | 0.110 |
Why?
|
| Dopamine Antagonists | 2 | 2005 | 291 | 0.110 |
Why?
|
| Electroshock | 1 | 2012 | 122 | 0.110 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2017 | 895 | 0.100 |
Why?
|
| Nerve Tissue Proteins | 1 | 2005 | 4455 | 0.100 |
Why?
|
| Receptors, Dopamine D2 | 2 | 2003 | 475 | 0.090 |
Why?
|
| Pentobarbital | 1 | 2010 | 155 | 0.090 |
Why?
|
| Dextroamphetamine | 1 | 2010 | 133 | 0.090 |
Why?
|
| Gene Deletion | 1 | 2018 | 2746 | 0.090 |
Why?
|
| Muscarinic Antagonists | 1 | 2010 | 137 | 0.090 |
Why?
|
| Stereoisomerism | 2 | 2006 | 624 | 0.080 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2010 | 238 | 0.080 |
Why?
|
| Avoidance Learning | 1 | 2010 | 233 | 0.080 |
Why?
|
| Quinoxalines | 1 | 2010 | 288 | 0.080 |
Why?
|
| Extracellular Space | 1 | 2010 | 596 | 0.080 |
Why?
|
| Time Perception | 1 | 2008 | 84 | 0.080 |
Why?
|
| Inhibitory Concentration 50 | 2 | 2007 | 459 | 0.080 |
Why?
|
| Central Nervous System Depressants | 1 | 2008 | 165 | 0.080 |
Why?
|
| Tropanes | 1 | 2006 | 52 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 1 | 2023 | 9300 | 0.070 |
Why?
|
| Analysis of Variance | 1 | 2015 | 6352 | 0.070 |
Why?
|
| Photic Stimulation | 1 | 2012 | 2017 | 0.070 |
Why?
|
| Mice, Knockout | 3 | 2018 | 14596 | 0.070 |
Why?
|
| Methylphenidate | 1 | 2010 | 476 | 0.070 |
Why?
|
| Phosphatidylinositols | 1 | 2005 | 292 | 0.060 |
Why?
|
| Feeding Behavior | 1 | 2017 | 3204 | 0.060 |
Why?
|
| Hydrolysis | 1 | 2005 | 682 | 0.060 |
Why?
|
| Caffeine | 1 | 2008 | 703 | 0.060 |
Why?
|
| Flupenthixol | 1 | 2003 | 12 | 0.060 |
Why?
|
| Quinpirole | 1 | 2003 | 33 | 0.060 |
Why?
|
| Pilocarpine | 1 | 2003 | 63 | 0.060 |
Why?
|
| Nanoparticles | 1 | 2015 | 1944 | 0.060 |
Why?
|
| Muscarinic Agonists | 1 | 2003 | 87 | 0.050 |
Why?
|
| Ethanol | 1 | 2008 | 1346 | 0.050 |
Why?
|
| Humans | 7 | 2023 | 752741 | 0.050 |
Why?
|
| Substance-Related Disorders | 1 | 2017 | 4290 | 0.050 |
Why?
|
| Acetylcholine | 1 | 2003 | 624 | 0.050 |
Why?
|
| Psychomotor Performance | 1 | 2008 | 1878 | 0.050 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2020 | 156 | 0.040 |
Why?
|
| Rats, Long-Evans | 1 | 2020 | 384 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 2 | 2018 | 22009 | 0.040 |
Why?
|
| Protein Conformation | 1 | 2007 | 4010 | 0.040 |
Why?
|
| Time Factors | 2 | 2015 | 40195 | 0.040 |
Why?
|
| Injections, Subcutaneous | 1 | 2020 | 680 | 0.040 |
Why?
|
| Schizophrenia | 1 | 2017 | 6923 | 0.040 |
Why?
|
| Corpus Striatum | 1 | 2005 | 1216 | 0.040 |
Why?
|
| Neurons | 1 | 2018 | 9439 | 0.040 |
Why?
|
| Injections, Intravenous | 1 | 2020 | 1420 | 0.040 |
Why?
|
| Cerebellum | 1 | 2005 | 1498 | 0.040 |
Why?
|
| Conditioning, Classical | 1 | 2020 | 371 | 0.040 |
Why?
|
| Mice, 129 Strain | 1 | 2018 | 383 | 0.040 |
Why?
|
| Brain | 2 | 2022 | 26598 | 0.030 |
Why?
|
| Acoustic Stimulation | 1 | 2020 | 1228 | 0.030 |
Why?
|
| United States | 1 | 2023 | 70772 | 0.030 |
Why?
|
| Cues | 1 | 2020 | 880 | 0.030 |
Why?
|
| Light | 1 | 2020 | 1332 | 0.030 |
Why?
|
| Serine | 1 | 2017 | 825 | 0.030 |
Why?
|
| Synaptic Transmission | 1 | 1999 | 1175 | 0.030 |
Why?
|
| Glutamic Acid | 1 | 2017 | 1164 | 0.030 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2017 | 1131 | 0.020 |
Why?
|
| Interpersonal Relations | 1 | 2018 | 1439 | 0.020 |
Why?
|
| Astrocytes | 1 | 2018 | 1301 | 0.020 |
Why?
|
| Mesylates | 1 | 2007 | 37 | 0.020 |
Why?
|
| Receptor, Muscarinic M1 | 1 | 2006 | 24 | 0.020 |
Why?
|
| Norepinephrine Plasma Membrane Transport Proteins | 1 | 2006 | 66 | 0.020 |
Why?
|
| Radioligand Assay | 1 | 2006 | 375 | 0.020 |
Why?
|
| Female | 4 | 2018 | 385090 | 0.020 |
Why?
|
| COS Cells | 1 | 2007 | 1154 | 0.020 |
Why?
|
| Hand Strength | 1 | 2008 | 457 | 0.020 |
Why?
|
| Alanine | 1 | 2007 | 575 | 0.020 |
Why?
|
| Hippocampus | 1 | 2018 | 3713 | 0.020 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 1 | 2006 | 322 | 0.020 |
Why?
|
| Protein Binding | 2 | 2007 | 9408 | 0.020 |
Why?
|
| Reading | 1 | 2008 | 558 | 0.020 |
Why?
|
| Comorbidity | 1 | 2017 | 10450 | 0.010 |
Why?
|
| Biological Transport | 1 | 2007 | 2121 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 2007 | 1795 | 0.010 |
Why?
|
| Reaction Time | 1 | 2008 | 2096 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 2006 | 3120 | 0.010 |
Why?
|
| Phenotype | 1 | 2018 | 16484 | 0.010 |
Why?
|
| Transfection | 1 | 2007 | 5882 | 0.010 |
Why?
|
| Data Interpretation, Statistical | 1 | 2007 | 2729 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2008 | 12202 | 0.010 |
Why?
|
| Young Adult | 1 | 2008 | 57267 | 0.000 |
Why?
|
| Adult | 1 | 2008 | 216658 | 0.000 |
Why?
|